Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Aim There is ongoing debate concerning the association of metformin with the risk of dementia in type 2 diabetes mellitus (T2DM). This study was conducted to evaluate the impact of metformin therapy on dementia in patients with T2DM. Materials and methods PubMed, Embase, Cochrane Library, Web of Science and the ClinicalTrials.gov website were searched until 9 April 2024. Cohort studies investigating the effects of metformin therapy compared with other antidiabetic drugs or no therapy in T2DM were included. The hazard ratio (HR) and the 95% confidence interval (CI) were computed using the random effects model. Results Twenty cohort studies (24 individual comparisons) involving 3 463 100 participants were identified. A meta-analysis revealed that people with T2DM who take metformin are linked to a lower incidence of all-cause dementia compared to non-user (n = 17, HR = 0.76, 95% CI = 0.65-0.91, p = 0.002, I 2 = 98.9%) and sulfonylureas (n = 5, HR = 0.88, 95% CI = 0.85-0.90, p 2 = 9.7%), but not to thiazolidinedione (n = 2, HR = 0.53, 95% CI = 0.08-3.41, p = 0.503, I 2 = 92.7%). Additionally, metformin showed favourable effects in non-specified T2DM (n = 19, HR = 0.75, 95% CI = 0.64-0.89), but not in newly diagnosed T2DM (n = 5, HR = 1.01, 95% CI = 0.81-1.27). Conclusion Metformin might correlate with a lower dementia incidence in people with T2DM. However, it is crucial to interpret these results with caution considering the high heterogeneity.

What this study adds

Evidence grade: Early

This is a pooled review of 3,463,100 participants. This meta-analysis of 20 cohort studies with over 3 million participants found that people with type 2 diabetes who take metformin were linked to a lower incidence of all-cause dementia compared with non-users and sulfonylureas, but not compared with thiazolidinedione. Reported effect size: HR 0.76 (95% CI 0.65-0.91) vs non-users overall; HR 1.01 (0.81-1.27) in newly diagnosed diabetes.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tang, C., Hao, J., Tao, F., Feng, Q., Song, Y., & Zeng, B. (2025). Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16192

Vancouver

Tang C, Hao J, Tao F, Feng Q, Song Y, Zeng B. Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16192. PMID: 39780315.

BibTeX

@article{tang2025-39780315,
  author  = {Tang, C. and Hao, J. and Tao, F. and Feng, Q. and Song, Y. and Zeng, B.},
  title   = {{Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis}},
  journal = {Diabetes, Obesity and Metabolism},
  year    = {2025},
  doi     = {10.1111/dom.16192},
  pmid    = {39780315},
  url     = {https://doi.org/10.1111/dom.16192}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This meta-analysis of 20 cohort studies with over 3 million participants found that people with type 2 diabetes who take metformin were linked to a lower incidence of all-cause dementia compared with non-users and sulfonylureas, but not compared with thiazolidinedione. The authors note the findings should be interpreted cautiously, and the study does not show that metformin treats or cures dementia.

Study details

Limitations

I2 of 98.9% means the pooled estimate is unreliable; time-related biases (immortal time, prevalent-user) affect many included studies; graded 'early' for that reason.

How this study scored 64/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 63 of the 98 points it could be judged on, which is 64 of 100. Total 64 of 100.63 of the 98 points we could judge = 64 of 100

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on free to read, so that was left out: it earned 63 of the 98 points we could judge it on, which is 64 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Diabetes, Obesity and Metabolism)
Journal's citation record 2 / 4 Diabetes Obesity and Metabolism: journal h-index 186 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 3,463,100 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 3 / 7 Cited 16 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Baoqi Zeng: h-index 11 (OpenAlex, whole career)
Institution's track record 1 / 3 Peking University: institution h-index 1,098 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39780315)
Free to read — / 2 Access not recorded — left out of this score
Points 63 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 63 of the 98 points we could judge it on is 64 out of 100.
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Prevention and risk from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →